Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HAI Floxuridine/Dex + Bevacizumab for Unresectable Liver Cancer
NCT00410956Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- May 2007
- Primary completion
- May 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC), sponsored by Memorial Sloan Kettering Cancer Center. Started May 2007; status: completed.
02
Drugs
bevacizumab
03
Conditions
hepatocellular carcinoma (HCC)intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT00410956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00410956.